616-34-2Relevant articles and documents
Sequential photo-addition of glycine methyl-ester to [60]fullerene
Skanji, Rym,Ben Messaouda, Mhamed,Zhang, Yongmin,Abderrabba, Manef,Szwarc, Henri,Moussa, Fathi
, p. 2713 - 2718 (2012)
While direct photo-addition of glycine-methyl-esters (GME) to [60]fullerene (C60) can yield a complex product mixture, only a fulleropyrrolidine (FP) mono-adduct has been characterized and the mechanism remains to be ascertained. We show here that visible light irradiation of a mixture of C 60 and GME in the presence of oxygen is a direct route to synthesize sequentially higher FP poly-adducts through an unprecedented cyclization-deamination mechanism. Each step of this mechanism leads to a FP adduct involving the correlated addition of two GME radicals and the departure of an ammonia molecule.
Participation of C-H Protons in the Dissociation of a Proton Deficient Dipeptide
Koirala, Damodar,Mistry, Sabyasachy,Wenthold, Paul G.
, p. 1313 - 1323 (2017)
The dissociation of anionic dipeptides Phe*Gly and GlyPhe*, where Phe* refers to sulfonated phenyl alanine, has been investigated by using ion trap mass spectrometry. The dipeptides undergo collision-induced dissociation (CID) to give the same products, indicating that they rearrange to a common structure before dissociation. The rearrangement does not occur with the dipeptide methyl esters. The structures of the b2 ions were investigated to determine the effect that having a remote, anionic site has on product formation. Comparison with the CID spectra for authentic structures shows that the b2 ion obtained from GlyPhe* has predominantly a diketopiperazine structure. The CID spectra for the Phe*Gly b2 ion and the authentic oxazolone are similar, but differences in intensity suggest a two-component mixture. Isotopic labeling studies are consistent with the formation of two products, with one resulting from loss of a non-mobile proton on the Gly α-carbon. The results are attributed to the formation of an oxazole and oxazolone enol product. Electronic structure calculations predict that the enol structure of the Phe*Gly b2 ion is lower in energy than the keto version due to intramolecular hydrogen bonding with the sulfonate group. [Figure not available: see fulltext.].
Studying Histone Deacetylase Inhibition and Apoptosis Induction of Psammaplin A Monomers with Modified Thiol Group
Bao, Yu,Xu, Qihao,Wang, Lin,Wei, Yunfei,Hu, Baichun,Wang, Jian,Liu, Dan,Zhao, Linxiang,Jing, Yongkui
, p. 39 - 47 (2021/01/26)
Psammaplin A (PsA) is a bromotyrosine disulfide dimer with histone deacetylase (HDAC) inhibition and acts through reduced monomer PsA-SH. We studied the connection of HDAC inhibition, cell growth inhibition, and apoptosis induction of PsA-SH by modifying the -SH group with deletion (6a) or replacement with hydroxamic acid (10b) or benzamide (12g). PsA-SH inhibits HDAC1/2/3 and 6a loses the HDAC inhibition ability. 10b inhibits HDAC1/2/3/6 while 12g shows selective inhibition of HDAC3. PsA-SH and 10b, but neither 6a nor 12g, induce apoptosis in human leukemia HL-60 cells associated with increased acetylation of Histone H3. PsA-SH and 10b inhibit growth of several solid tumor cell lines in vitro and Lewis lung cancer cell growth in vivo. PsA-SH is a simple scaffold for developing selective HDAC inhibitors and induces apoptosis through inhibiting HDAC1/2.
PSA derivatives with HDAC3 inhibitory activity and application thereof
-
Paragraph 0079; 0082-0084, (2020/08/27)
The invention belongs to the technical field of medicines. The invention relates to a series of PSA derivatives with antitumor activity. The invention specifically relates to compounds containing (E)-3-bromo-4-hydroxyphenyl-2-oximido fragments and pharmaceutically acceptable salts and hydrates of the compounds, and pharmaceutical compositions containing the compounds and the pharmaceutically acceptable salts and hydrates thereof as active ingredients, and uses of the compounds and the pharmaceutically acceptable salts and hydrates thereof and the pharmaceutical compositions in preparation of histone deacetylase inhibitors and drugs for treatment and/or prevention of cancers. The compounds, and the pharmaceutically acceptable salts and hydrates thereof are represented by a formula I. In theformula I, R and n are described in the claims and the specification.